

#### **VEGF R2/KDR**

Catalog # PVGS1823

#### **Specification**

#### **VEGF R2/KDR - Product Information**

Primary Accession **Species** Human P35968-1

**Sequence** 

Ala20-Glu764

### **Purity**

> 95% as determined by Bis-Tris PAGE<br/>> > 95% as determined by HPLC

#### **Endotoxin Level**

Less than 1EU per µg by the LAL method.

### **Biological Activity**

Immobilized VEGF R2/KDR[Biotin], His&Avi, Human (Cat.No.: Z03970) at 0.5  $\mu$ g/ml (100  $\mu$ l/Well) on the streptavidin precoated plate can bind Anti-VEGF R2 Antibody, hFc Tag

# **Expression System**

**HEK293** 

#### **Theoretical Molecular Weight**

86.2 kDa

Formulation

Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).

#### Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>0 more than 100  $\mu$ g/ml.

## Storage & Stability


Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

### **VEGF R2/KDR - Additional Information**

# **Target Background**

Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.

#### **VEGF R2/KDR - Protein Information**





# **VEGF R2/KDR - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

**VEGF R2/KDR - Images**